At present, the clinical first-line drugs for AD are directly targeted on te brain, such as the NMDA receptor antagonist (Memantine), AChE inhibitor (Donepezil, Galantamine, and Rivastigmine), and Serotonin and dopamine receptor antagonists (Quetiapine, Trifluperidol, and Risperidone). The gene discussed is ACHE; the disease is Alzheimer disease.